Under the non-exclusive agreement, Pfizer will utilize Novavax’s Matrix-M adjuvant in products across two disease areas, with Novavax receiving a $30 million upfront payment. Additionally, the ...

Novavax, Inc. receives a Hold rating, reflecting improved prospects after its Sanofi partnership and upgraded 2025 revenue guidance to $1–1.05 billion. The SNY deal provides upfront payments, ...

The CDC said on Friday, Jan. 9, 2026, that respiratory illness activity remains high nationwide. Flu cases are elevated and expected to stay that way for several more weeks. RSV levels are also high ...

Management provided a 2026 adjusted total revenue target of $230 million to $270 million, including $35 million to $45 million of Nuvaxovid product sales under existing orders, $40 million to $50 ...